×

Fact Sheet: Managing Treatment For Individuals With Major Depressive Disorder (MDD) - Top 10 New Resources On PsychU

GETTYSBURG, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Fact Sheet | New articles, resources, and presentations related to managing treatment for individuals with major depressive disorder (MDD) now available at no charge via PsychU's online community and knowledge center at www.psychu.org.

  1. Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) (Streaming Presentation) — An overview of some important issues in recognizing and responding to inadequately treated major depressive disorder, including characteristics associated with a poor response to antidepressant treatment, nonpharmacologic therapies for MDD, and significant challenges surrounding the treatment of MDD.
  2. Integration of Depression & Primary Care: Barriers To Adoption (Research Summary) — Integration of depression care and primary care faces many barriers (e.g., patient comorbidities, patient and family sociodemographic factors, provider culture and supply, financial cost to patients and providers, and organizational constraints) that may impede the delivery and access to intervention and care.
  3. Economics Of Collaborative Care For Management Of Depressive Disorders A Community Guide Systematic Review (Research Summary) — Previous studies have shown that the economic burden of Major Depression in the US can reach up to $42 billion (all costs quoted in the report were adjusted to 2008 US dollars), and a substantial proportion of these costs relate to missing work (absenteeism) or being present at work but feeling too ill to be fully productive (presenteeism).
  4. Risk Factors For Treatment Resistance In Unipolar Depression: A Systematic Review (Research Summary) — Many patients do not respond to initial therapy for depression, and identifying early indicators of poor response could impact clinical practice and disease burden.
  5. Understanding The Cost Of Treatment-Resistant Depression (Resource) — There is no clear consensus in the definition of Treatment Resistant Depression (TRD). This lack of standardized definition creates problems not only for patients and diagnosticians but for payers as well.
  6. People With Depression & Comorbid Behavioral Health Disorders Seek Treatment More Actively Than Those Without Comorbid Disorders (News) — Adults with major depressive disorder (MDD) and comorbid psychiatric disorders, especially panic, generalized anxiety, drug dependence, and dysthymic disorders, receive treatment for depression more quickly after MDD onset than people who have MDD but no comorbid disorders.
  7. Lifestyle Management Of Unipolar Depression (Research Summary) — Management of depression in current clinical practice focuses mostly on two strategies: medication and psychotherapy. Certain lifestyle factors such smoking, alcohol dependence, sedentary lifestyle and poor diet may influence the risk of depression, and clinical trials have demonstrated a more modest effect size in favor of exercise (effect size -0.31, 95% CI: -0.63, 0.01) over standard treatment for depression.
  8. Depression Linked To 4.8 Lost Workdays Per Employee Per Quarter (News) — In the United States, employees with depression average 4.8 lost workdays per employee per quarter, and another 11.5 days of reduced productivity. In any given year, about 9.5% of American adults experience depressive symptoms, but rates of depression vary by occupation and industry.
  9. 19% Of Residential Care Communities Screen For Depression (News) — In 2012, only 19% of residential care communities (RCC) screened residents for depression. A higher percentage of RCCs with more than 50 beds screened for depression (22%) as part of the admission process, while only 17% of smaller communities (4-25 beds) screened for depression.
  10. CMS Quality Initiatives: Behavioral Health Measures, 2014 (Resource) — What began in 2002 with the launch of the Centers for Medicare and Medicaid Services (CMS) Nursing Home Quality Initiative now involves as many as 22 separate CMS quality programs. The CMS quality initiatives touch nearly every aspect of the health care system, including behavioral health – currently there are over 900 (not mutually exclusive) quality measures in use across all programs.

See what other content is available on the PsychU community by visiting: http://www.psychu.org/
___________________________________________________________________________________________________________________________________________
Recognizing & Responding To Inadequately Treated Major Depressive Disorder (MDD)
A new educational program available to clinical and executive teams across the country
An overview of the important issues in recognizing and responding to inadequately treated major depressive disorder including:

• Links between depression and other illnesses
• Societal costs associated with MDD
• Challenges surrounding the treatment of MDD

These programs are available at no charge through the PsychU "Request A Presentation" program
___________________________________________________________________________________________________________________________________________
About PsychU

PsychU is a new online community and knowledge center dedicated to understanding, sharing, and evolving best practices in mental health treatment. Through the exchange of information, experience, and ideas, PsychU members aim to shift the current trajectory of mental health care and improve the future outlook for individuals with mental illnesses.

The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.

PsychU is supported by Otsuka America Pharmaceutical, Inc. and Lundbeck, L.L.C., committed supporters of the mental health treatment community. No CME credits are available through any of the resources provided by PsychU. The PsychU online community and website is managed by OPEN MINDS. Some of the contributors may be paid consultants for Otsuka America Pharmaceuticals, Inc. and/or Lundbeck, L.L.C. Medical writing support provided by Oxford PharmaGenesis, Inc. who received payment for their services from Otsuka America Pharmaceutical, Inc. and Lundbeck, L.L.C.

For additional questions or information, contact the PsychU Team at 855-559-6829 or info@psychu.org.

CONTACT: PsychU Phone: 855-559-6829 E-mail: info@psychu.orgSource: PsychU